ANSAID Drug Patent Profile

Which patents cover Ansaid, and what generic alternatives are available?

Ansaid is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in ANSAID is flurbiprofen. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the flurbiprofen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ansaid

A generic version of ANSAID was approved as flurbiprofen by TEVA on May 31^st, 1995.

Summary for ANSAID

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	168
Clinical Trials:	3
Patent Applications:	3,070
DailyMed Link:	ANSAID at DailyMed

Recent Clinical Trials for ANSAID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 1
United States Army Research Institute of Environmental Medicine	Phase 1
National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2

See all ANSAID clinical trials

US Patents and Regulatory Information for ANSAID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	ANSAID	flurbiprofen	TABLET;ORAL	018766-002	Oct 31, 1988		DISCN	Yes	No
Pharmacia And Upjohn	ANSAID	flurbiprofen	TABLET;ORAL	018766-003	Oct 31, 1988		DISCN	Yes	No

Expired US Patents for ANSAID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmacia And Upjohn	ANSAID	flurbiprofen	TABLET;ORAL	018766-002	Oct 31, 1988	3,755,427
Pharmacia And Upjohn	ANSAID	flurbiprofen	TABLET;ORAL	018766-003	Oct 31, 1988	3,793,457
Pharmacia And Upjohn	ANSAID	flurbiprofen	TABLET;ORAL	018766-003	Oct 31, 1988	3,755,427
Pharmacia And Upjohn	ANSAID	flurbiprofen	TABLET;ORAL	018766-002	Oct 31, 1988	3,793,457

International Patents for ANSAID

See the table below for patents covering ANSAID around the world.

Country	Patent Number	Title	Estimated Expiration
France	5738
France	5737
Czechoslovakia	163156
Sweden	329843
France	1430359	Nouveaux dérivés de phénylalcanes et leur procédé de préparation
Netherlands	152540

ANSAID Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): A Focus on Ansaid

Introduction

Non-steroidal anti-inflammatory drugs (NSAIDs) are a crucial segment of the pharmaceutical industry, providing relief for various pain-related conditions. Ansaid, a brand name for the NSAID flurbiprofen, is part of this broader market. Here, we will delve into the market dynamics and financial trajectory of NSAIDs, with a focus on the factors influencing the market and the potential outlook for drugs like Ansaid.

Global NSAIDs Market Size and Growth

The global NSAIDs market is substantial and growing. As of 2024, the market size was estimated at USD 22.58 billion and is projected to grow at a CAGR of 5.66% from 2025 to 2030[1][4].

Key Drivers of Market Growth

Several factors are driving the growth of the NSAIDs market:

Increasing Prevalence of Chronic Pain

The global rise in chronic pain prevalence is a significant driver. Conditions such as arthritis, headaches, migraines, toothaches, and menstrual pain contribute to the increased demand for NSAIDs[1][4].

Aging Population

The growing geriatric population is more susceptible to conditions requiring pain relief, thereby increasing the demand for NSAIDs. By 2050, the number of older people worldwide is projected to more than double, from 761 million in 2021 to 1.6 billion[4].

Expanded OTC Availability

The broader availability of over-the-counter (OTC) NSAIDs has expanded their reach and convenience, making them more accessible to consumers. This has particularly boosted the market in regions like Europe and North America[1][3].

Regulatory Support and New Product Approvals

Regulatory support for innovative formulations and the development of combination therapies also contribute to market growth. New product approvals and launches, such as Dr. Reddy's Laboratories' diclofenac sodium topical gel, enhance the market's momentum[1][4].

Regional Market Dynamics

Europe

The Europe NSAIDs market is witnessing significant growth driven by increasing awareness of pain management solutions and the rising prevalence of chronic pain conditions. The UK, in particular, is seeing growth due to the National Health Service (NHS) emphasizing the importance of NSAIDs in treatment protocols[1].

North America

In North America, the high prevalence of arthritis, with approximately 53.2 million adults in the U.S. affected, drives the demand for NSAIDs. The Centers for Disease Control and Prevention (CDC) reports that women are more affected than men, further contributing to the market's growth[4].

Brazil and MEA

In Brazil, the market is growing due to an increasing focus on healthcare accessibility and the prevalence of pain-related disorders. Government policies to expand healthcare coverage support this growth. The Middle East and Africa (MEA) region is also seeing growth due to rising awareness of chronic pain management and an increasing incidence of musculoskeletal disorders[1].

Saudi Arabia

Saudi Arabia's NSAIDs market is expanding as part of the country's Vision 2030 framework, which prioritizes improving health outcomes and increasing access to effective pain relief solutions[1].

Financial Trajectory

Revenue Projections

The global NSAIDs market is expected to reach USD 33.55 billion by 2032, up from USD 21.56 billion in 2024. This growth is driven by the increasing demand for pain relief solutions and the expanding product portfolio of NSAIDs[4].

Distribution Channels

Retail pharmacies dominate the distribution of NSAIDs, holding a significant market share. Online pharmacies are also gaining traction, offering convenience and accessibility to consumers[3][4].

Competitive Landscape

The NSAIDs market is competitive, with key players such as Bayer AG, Boehringer Ingelheim International GmbH, Johnson & Johnson, and Haleon PLC. These companies are investing in research and development to introduce new formulations and expand their product lines[3].

Consumer Trends and Preferences

Shift to OTC Medications

Consumers are increasingly preferring OTC medications for pain relief due to their convenience and accessibility. This trend is driven by the rising awareness of the benefits of self-medication and the availability of a wide range of OTC NSAIDs[3].

Preference for Safer Alternatives

The concern over opioid addiction and abuse has led to a rise in the use of NSAIDs as safer alternatives for managing pain. This shift is supported by healthcare providers and regulatory bodies, further boosting the demand for NSAIDs[4].

Advancements in Drug Delivery Technologies

Topical and Sustained-Release Formulations

Advancements in drug delivery technologies, such as topical and sustained-release formulations, have expanded the options available for pain management. These innovations cater to diverse patient needs and preferences, enhancing the market's growth potential[4].

Key Takeaways

• The global NSAIDs market is growing significantly, driven by the increasing prevalence of chronic pain and the aging population.
• Expanded OTC availability and regulatory support for innovative formulations are key drivers.
• Regional markets, such as Europe, North America, Brazil, and the MEA region, are experiencing growth due to various local factors.
• The financial trajectory indicates a robust growth path, with the market expected to reach USD 33.55 billion by 2032.
• Consumer trends favor safer alternatives and convenient OTC medications.
• Advancements in drug delivery technologies are enhancing market dynamics.

FAQs

What is the current market size of the global NSAIDs market?

The global NSAIDs market size was estimated at USD 22.58 billion in 2024[1].

What is the projected CAGR for the NSAIDs market from 2025 to 2030?

The NSAIDs market is expected to grow at a CAGR of 5.66% from 2025 to 2030[1].

Which region is leading the NSAIDs market growth?

North America remains the leading contributor to the NSAIDs market, driven by the high prevalence of arthritis[4].

What are the key drivers of the NSAIDs market growth?

Key drivers include the increasing prevalence of chronic pain, the growing geriatric population, and the expanded availability of OTC NSAIDs[1][4].

How are advancements in drug delivery technologies impacting the NSAIDs market?

Advancements in topical and sustained-release formulations are expanding the options for pain management, catering to diverse patient needs and preferences[4].

Sources

1. Grand View Research: Non-steroidal Anti-inflammatory Drugs Market Report, 2030
2. Investing.com: Ascendis Pharma's Q1 2024 Financial Results: A Renewed Perspective
3. Market.us: Over The Counter Analgesics Market Size, Share | CAGR of 4.0%
4. GlobeNewswire: Non-Steroidal Anti-Inflammatory Drugs Market Size to Worth USD 33.55 Bn by 2032